olfactory receptor family 2 subfamily T member 33Genealiases: OR1-56 · OR2T32
Q-omics provides the consensus-scored OR2T33 profile across patient tissues and cancer cell-line models. OR2T33 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, OR2T33 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, OR2T33 RNA expression shows 7,299 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LIHC, THCA, and LAML as cancer lineages where OR2T33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2T33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2T33 survival associations across molecular data types. OR2T33 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2T33 RNA expression–survival associations across cancer types. High OR2T33 expression shows unfavorable associations in LIHC, BLCA, COAD, OV and MESO, but favorable associations in BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for OR2T33 RNA expression.
This table summarizes OR2T33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR2T33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2T33 shows lower tumor expression in THCA and COAD. The THCA box plot shows higher OR2T33 RNA expression in normal versus tumor tissue (log2 FC = −0.248, t-test p = .001).
This table shows molecular features associated with OR2T33 in patient tissues and cancer cell lines. In patient samples, OR2T33 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, OR2T33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
